Lack of the mediators of innate immunity attenuate the development of autoimmune diabetes in mice

Journal of Autoimmunity

Volumn 21, Issue 3, 2003, Pages 239-246

  Lukic, M L ^a   Mensah Brown, E ^a   Wei, X ^b   Shahin, A ^a   Liew, F Y ^b  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Autoimmunity; Diabetes; Immuno intervention; Interleukin 15 (IL 15); Interleukin 18 (IL 18)

Indexed keywords

ANTIDIABETIC AGENT; CYTOKINE; GLUCOSE; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 18; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; AUTOIMMUNE DISEASE; CELL INFILTRATION; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; EVALUATION; GLUCOSE BLOOD LEVEL; IMMUNITY; KNOCKOUT MOUSE; MALE; MEDIATOR; MONONUCLEAR CELL; MOUSE; MOUSE STRAIN; MUTANT; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; WILD TYPE;

EID: 0242492516     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-8411(03)00115-X     Document Type: Conference Paper

References (38)

1. Liew F.Y., McInnes I.B. Role of interleukin 15 and interleukin 18 in inflammatory response. Ann Rheum Dis. 61:(2:ii):2002;100-102.
2. Schluns K.S., Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol. 3:(4):2003;269-270.
3. Hill N., Sarvetnick N. Cytokines: promoters and dampeners of autoimmunity. Curr Opin Immunol. 14:(6):2002;791-797.
4. Frigerio S., Hollander G.A., Zumsteg U. Functional IL-18 is produced by primary pancreatic mouse islets and NIT-1 beta cells and participates in the progression towards destructive insulitis. Horm Res. 57:(3-4):2002;94-104.
5. Nicoletti F., Conget I., Di Marco R., Speciale A.M., Morinigo R., Bendtzen K., et al. Serum levels of the interferon-gamma-inducing cytokine interleukin-18 are increased in individuals at high risk of developing type I diabetes. Diabetologia. 44:(3):2001;309-311.
6. Kretowski A., Mironczuk K., Karpinska A., Bojaryn U., Kinalski M., Puchalski Z., et al. Interleukin-18 promoter polymorphisms in type 1 diabetes. Diabetes. 51:(11):2002;3347-3349.
7. Rothe H., Hausmann A., Kolb H. Immunoregulation during disease progression in prediabetic NOD mice: inverse expression of arginase and prostaglandin H synthase 2 vs. interleukin-15. Horm Metab Res. 34:(1):2002;7-12.
8. Rossini A.A., Williams R.M., Appel M.C., Like A.A. Complete protection from low-dose streptozotocin-induced diabetes in mice. Nature. 276:(5684):1978;182-184.
9. Kolb-Bachofen V., Epstein S., Kiesel U., Kolb H. Low dose streptozotocin induced diabetes in mice. Diabetes. 37:1988;21-27.
10. Pechhold K., Patterson N.B., Blum C., Fleischacker C.L., Boehm B.O., Harlan D.M. Low dose streptozotocin-induced diabetes in rat insulin promoter-mCD80-transgenic mice is T cell autoantigen-specific and CD28 dependent. J Immunol. 166:2001;2531-2539.
11. Lukic M.L., Al-Sharif R., Mostarica M., Bahr G., Behbehani K. Immunological basis of the strain differences in susceptibility to low-dose streptozotocin-induced diabetes in rats. Imhof B., et al. Lymphatic tissues and in vivo immune responses. 1991;643-647 Marcel Dekker, New York.
12. Stostic-Grujicic S., Maksimovic D., Badovinac V., Samardzic T., Trajkovic V., Lukic M., et al. Antidiabetogenic effect of pentoxifylline is associated with systemic and target tissue modulation of cytokines and nitric oxide production. J Autoimmun. 16:(1):2001;47-58.
13. Holstad M., Sandler M. A transcriptional inhibitor of TNF-α prevents diabetes induced by multipe low-dose streptozotocin injections in mice. J Immunol. 16:(4):2001;441-447.
14. Mensah-Brown E.P., Stosic Grujicic S., Maksimovic D., Jasima A., Shahin A., Lukic M.L. Downregulation of apoptosis in the target tissue prevents low-dose streptozotocin-induced autoimmune diabetes. Mol Immunol. 38:(12-13):2002;941-946.
15. Lukic M.L., Stosic-Grujicic S., Ostojic N., Chan W.L., Liew F.Y. Inhibition of nitric oxide generation affects the induction of diabetes by streptozotin in mice. Bichem Biophys Res Commun. 15:(178(3)):1991;913-920.
16. Rydgren T., Sandler S. Efficacy of 1400 W, a novel inhibitor of inducible nitric oxide synthase, in preventing interleukin-1beta-induced suppression of pancreactic islet function in vitro and multiple low-dose streptozotocin-induced diabetes in vivo. Eur J Endocrinol. 147:(4):2002;543-551.
17. Wei X., Leung B.P., Arthur H.M.L., McInnes I.B., Liew F.Y. Reduced incidence and severity of collagen-induced arthritis in micelacking IL-18. J Immunol. 166:2001;517-521.
18. Gracie J.A., Forsey R.J., Chan W.L., Gilmour A., Leung B.P., Greer M.R., et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest. 104:1999;1337-1339.
19. Wei X., Leung B.P., Niedbala W., Piedrafita D., Feng G., Sweet M., et al. Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J Immunol. 163:1999;2821.
20. Lukic M.L., Ejdus L., Pravica V., Shahin A., Stosic S., Mosatarica M., et al. Downregulation of Th-1 mediated autoimmune pathology. Lukic M., et al. Immunoregulation in health and diseases. 1997;265-278 Academic Press, London/ New York.
21. Wachlin G., Augstein P., Schröder D., Kuttler B., Klöting I., Heinke P., et al. IL-1β, IFN-γ and TNF-α increase vulnerability of pancreatic beta cells to autoimmune destruction. J Autoimmun. 20:2003;303-312.
22. Bach J.F. Immunotherapy of insulin-dependent diabetes mellitus. Curr Opin Immunol. 13:2001;601-605.
23. Wu A.J., Hua H., Munson S.H., McDevitt H.O. Tumor necrosis factor-alpha regulation of CD4+CD25+ T cells levels in NOD mice. Proc Natl Acad Sci U S A. 99:(19):2002;12287-12292.
24. McDevitt H., Munson S., Ettinger R., Wu A. Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity. Arthritis Res. 4:2002;S141-S152.
25. McInnes I.B., Gracie J.A., Leung B.P., Wei X.Q., Liew F.Y. Interleukin 18: a pleiotropic participant in chronic inflammation. Immunol Today. 21:2000;312-315.
26. McInnes I.B., Gracie J.A., Liew F.Y. Interleukin-18: a novel cytokine in inflammatory rheumatoid disease. Arthritis Rheum. 44:(7):2001;1716-1717.
27. Shi F.D., Takeda K., Akira S., Sarvetnick N., Ljunggren H.G. IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. J Immunol. 165:2000;3099-3104.
28. Esfandiari E., McInnes I.B., Lindop G., Huang F.P., Field M., Komai-Koma M., et al. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J Immunol. 167:2001;5338-5347.
29. Monteleone G., Trapasso F., Parrello T., Biancone L., Stella A., Iuliano R., et al. Bioactive IL-18 expression is upregulated in Crohn's disease. J Immunol. 163:1999;143.
30. Pizarro T.T., Michie M.H., Bentz M., Woraratanadharm J., Smith M.F. Jr, Foley E., et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol. 162:1999;6829.
31. Nakanishi K., Youshimoto T., Tsutsui H., Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol. 19:2001;423-474.
32. Rothe H., Hausmann A., Casteels K., Okamura H., Kurimoto M., Burkart V., et al. IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th 1-dependent destructive insulitis. J Immunol. 163:1999;1230.
33. Rothe H., Jenkins N.A., Copeland N.G., Kolb H. Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near Idd2. J Clin Invest. 99:1997;469.
34. Rothe H., Ito Y., Kolb H. Disease resistant, NOD-related strains reveal checkpoints of immunoregulation in the pancreas. J Mol Med. 79:(4):2001;190-197.
35. McInnes I.B., Liew F.Y. Interleukin-15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol Today. 19:1998;75-79.
36. Losy J., Niezgoda A., Zaremba J. IL-15 is elevated in sera of patients with relapsing-remitting multiple sclerosis. Folio Neuropathol. 40:(3):2002;151-153.
37. Weng N.P., Liu K., Catalfamo M., Li Y., Henkart P.A. IL-15 is a growth factor and an activator of CD8 memory T cells. Ann N Y Acad Sci. 975:2002;46-56.
38. Gonzalez A.I., Wang B., Katz J., Benoist C., Maths D. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci U S A. 93:(6):1996;2260-2263.